Durata Therapeutics (DRTX) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'Durata Therapeutics, Inc.	'
Entity Central Index Key	'0001544116	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	26,641,975

Consolidated_Balance_Sheet

Consolidated Balance Sheet (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$20,669	$36,853
Short-term investments	20,872	22,880
Prepaid expenses and other current assets	3,955	3,367
Total current assets	45,496	63,100
Acquired in process research and development	15,292	15,292
Goodwill	5,811	5,811
Property and equipment, net	831	897
Restricted cash	997	1,147
Deferred charge	10,081	10,081
Other assets	3,904	3,816
Total assets	82,412	100,144
Current liabilities:	'	'
Accounts payable	3,204	5,275
Accrued expenses	8,912	7,116
Current portion of long-term debt	313	'
Income taxes payable	573	1,609
Total current liabilities	13,002	14,000
Long-term debt	24,687	25,000
Non-current income tax payable	1,377	1,377
Contingent consideration	23,587	20,889
Other liabilities	289	299
Total liabilities	62,942	61,565
Commitments and contingencies (note 9)	'	'
Stockholders' equity:	'	'
Common stock, $0.01 par value; 125,000,000 shares authorized at March 31, 2014 and December 31, 2013; 26,635,814 and 26,625,749 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	266	266
Preferred stock, $0.01 par value; 5,000,000 shares authorized at March 31, 2014 and December 31, 2013; no shares issued and outstanding at March 31, 2014 or December 31, 2013	'	'
Additional paid-in capital	208,602	207,754
Accumulated deficit during the development stage	-189,398	-169,441
Total stockholders' equity	19,470	38,579
Total liabilities and stockholders' equity	$82,412	$100,144

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	26,635,814	26,625,749
Common stock, shares outstanding	26,635,814	26,625,749
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (USD $)	3 Months Ended		53 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Operating expenses:	'	'	'
Research and development expenses	$9,009	$11,092	$133,170
General and administrative expenses	7,237	4,050	43,621
Acquisition related charges, net	2,698	284	12,295
Operating loss	18,944	15,426	189,086
Other (income) expense:	'	'	'
Interest expense	895	108	3,121
Loss on early extinguishment of debt	'	'	2,228
Interest income	-13	-15	-134
Other income	'	'	-501
Total other (income) expense	882	93	4,714
Loss before income tax expense (benefit)	19,826	15,519	193,800
Income tax expense (benefit)	131	248	-4,402
Net loss	($19,957)	($15,767)	($189,398)
Net loss per common share - Basic and Diluted	($0.75)	($0.86)	'
Weighted average common shares - Basic and Diluted	26,633,284	18,367,540	'

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	3 Months Ended		53 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities:	'	'	'
Net loss	($19,957)	($15,767)	($189,398)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Loss on early extinguishment of debt	'	'	2,228
Depreciation and amortization	66	59	333
Stock based compensation expense	779	558	5,903
Acquisition related charges, net	2,698	284	12,295
Non-cash interest expense	20	32	589
Deferred income taxes	'	'	-6,824
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other current assets	-432	1,854	-2,439
Contingent receivable	'	'	5,421
Deferred charge	'	1,181	-10,081
Other assets	-67	'	-677
Accounts payable	-2,071	2,668	3,204
Accrued expenses	1,796	-6,887	7,754
Income taxes payable/receivable	-1,036	-1,533	109
Other liabilities	-11	104	288
Net cash used in operating activities	-18,215	-17,447	-171,295
Cash flows from investing activities:	'	'	'
Acquisition of in process research and development	'	'	-10,000
Purchases of property and equipment	'	-402	-1,164
Purchases of short-term investments	-3,998	-2,998	-46,980
Proceeds from sale of short-term investments	6,000	2,000	26,000
Other investing activities	'	-291	-1,141
Other assets	'	'	-40
Net cash provided by (used in) investing activities	2,002	-1,691	-33,325
Cash flows from financing activities:	'	'	'
Proceeds from issuance of Series A Preferred Stock	'	'	77,198
Proceeds from issuance of common stock, net	'	'	128,016
Payment of offering costs	'	'	-3,057
Proceeds from issuance of long-term debt	'	20,000	45,000
Payment of debt financing fees	-41	-525	-1,125
Payment to retire long-term debt	'	'	-21,694
Proceeds from stock options exercised	65	48	266
Excess tax benefit on stock-based awards	5	'	106
Proceeds from receipt of contingent receivable	'	'	579
Net cash provided by financing activities	29	19,523	225,289
Net (decrease) increase in cash	-16,184	385	20,669
Cash and cash equivalents, beginning of year and period	36,853	32,257	'
Cash and cash equivalents, end of year and period	20,669	32,642	20,669
Non-cash financing activities:	'	'	'
Debt financing costs included in current liabilities	0	115	'
Equity offering costs included in current liabilities	0	225	'
Conversion of Series A Preferred Stock to common stock (shares)	'	'	77,197,936
Cash paid for interest	875	76	2,532
Cash paid for income taxes	$1,162	$600	$13,069

Nature_of_Business_Organizatio

Nature of Business, Organization and Liquidity	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Nature of Business, Organization and Liquidity	'
	-1	Nature of Business, Organization and Liquidity
	Durata Therapeutics, Inc. and subsidiaries (a development stage company) (the Company) is a Delaware corporation and has its principal place of business in Chicago, Illinois. The Company is a pharmaceutical company focused on the development and commercialization of new therapeutics for patients with infectious diseases and acute illnesses. The Company was incorporated on November 4, 2009. In December 2009, the Company entered into an agreement with Pfizer Inc. (Pfizer) to acquire Vicuron Pharmaceuticals Inc. (Vicuron) (see note 4, Acquisition—Milestone Payment).
	To date, the Company has not generated any revenues and has financed its operations primarily through private placements of its preferred stock, its initial public offering of its common stock in July 2012 (see note 6, Stockholders’ Equity and Stock Compensation), a secured debt financing completed in March 2013 and refinanced with a new lender in October 2013 (see note 5, Long-term Debt), and a public offering of its common stock in April 2013 (see note 6, Stockholders’ Equity and Stock Compensation). The Company expects to continue to incur significant expenses to seek marketing approval for dalbavancin, and possibly other product candidates, establish a commercial organization, conduct clinical trials for additional indications for dalbavancin, including osteomyelitis, diabetic foot infection and pneumonia, as well as new dosing strategies and formulations, and manufacture product. As recently announced, the Company began enrollment in a Phase 3b clinical trial to evaluate the efficacy and safety of a single 1,500 mg dose of dalbavancin infused over 30 minutes in adult patients with ABSSSI caused by susceptible Gram-positive bacteria. The Company had a net loss of $20.0 million for the three months ended March 31, 2014 and had a deficit accumulated during the development stage of $189.4 million from inception until March 31, 2014.
	Based on the Company’s existing cash and cash equivalents and short-term investments, the Company estimates that it has sufficient funding to sustain its operations through early 2015. The Company estimates that such funds will be sufficient to enable it to seek marketing approval in the United States and the European Union for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI), and, if approved, to commercially launch dalbavancin in the United States and possibly Western Europe, as well as explore the development of dalbavancin for additional indications and new dosing strategies, including the Phase 3b clinical trial mentioned above, and formulations. The Company has based this estimate on assumptions that may prove to be wrong, and it could use its available capital resources sooner than it currently expects.
	The Company also believes it has other financing alternatives available, including the incremental $15.0 million the Company is required to borrow from PDL BioPharma, Inc. (PDL) upon marketing approval of dalbavancin in the United States (see note 5, Long-term Debt) and the option to borrow an additional $30.0 million, to fund additional activities until its operations generate adequate operating cash flows, which include additional equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company also has limited fixed commitments for uses of cash and has the intent and ability, if necessary, to delay or eliminate expenditures until adequate funding is available.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	-2	Summary of Significant Accounting Policies
		(a)	Basis of Presentation, Principles of Consolidation and Unaudited Interim Results
	The unaudited accompanying consolidated financial statements of the Company are prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the SEC) and generally accepted accounting principles in the United States of America (GAAP) for condensed consolidated financial information. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. All intercompany accounts and transactions have been eliminated. These financial statements should be read in connection with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the SEC on March 14, 2014.
	The results for the three month period ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period or for any other future year.
		(b)	Use of Estimates
	The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
		(c)	Development Stage Company
	The Company’s primary activities since inception have been organizing and staffing the Company, business planning, raising capital and acquiring and developing dalbavancin. Accordingly, the Company is considered to be in the “development stage” and has prepared the accompanying consolidated financial statements in accordance with the provisions of the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) No. 915, Accounting for Development Stage Entities.
		(d)	Cash and Cash Equivalents and Restricted Cash
	The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash resources principally in money market funds.
	Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted in the next twelve months, the restricted cash account is classified as current. Included within restricted cash and prepaid expenses and other current assets on the Company’s consolidated balance sheet are certificates of deposit for a total of $1.1 million as of each March 31, 2014 and December 31, 2013, which are being held by a third party bank as collateral for the irrevocable letters of credit issued in connection with the Company’s two office leases (see note 9, Commitments and Contingencies).
		(e)	Financial Instruments
	The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is established that prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:
	Level 1:		Observable inputs such as quoted prices in active markets for identical assets or liabilities;
	Level 2:		Inputs other than the quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly; and
	Level 3:		Unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. See note 3, Financial Instruments, for additional information.
		(f)	Short-term Investments
	As of March 31, 2014, cash equivalents and short-term investments consist of investments in money market accounts, federal agency bonds and corporate entity commercial paper and bonds that are classified as available for sale pursuant to ASC 320, Investments—Debt and Equity Securities. The Company classifies investments available to fund current operations as current assets on its balance sheet. Investments are classified as long-term assets on the balance sheet if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. All of the Company’s investments are classified as current.
	The fair value of these securities is based on quoted prices for identical or similar assets. If a decline in the fair value is considered other-than-temporary the unrealized loss, if any, would be transferred from other comprehensive loss to the statement of operations. There were no charges taken for other-than-temporary declines in fair value of short-term investments during the three month period ended March 31, 2014. Realized gains and losses are determined using the specific identification method and are included in interest income in the statement of operations. Realized gains and losses recognized during the three month period ended March 31, 2014 were immaterial.
	The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers its intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment and changes in value subsequent to year end. As of December 31, 2013, there were no investments with a fair value that was lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period. See note 3, Financial Instruments, for further information.
		(g)	Deferred Financing Costs
	The Company capitalizes certain legal, accounting and other fees that are directly associated with in-process debt and equity financings as current assets until such financings occur. In the case of an equity financing, after occurrence, these costs are recorded in equity, net of proceeds received. In the case of a debt financing, these costs are recorded as other assets and amortized to interest expense over the term of the debt.
	As of March 31, 2014, the Company recorded debt financing costs of $0.4 million in connection with the debt financing completed in October 2013. The debt financing costs recorded in connection with the debt financing completed in March 2013 were expensed at the time the debt was repaid (see note 5, Long-term Debt, for more information). The Company also incurred offering costs of $0.4 million in connection with the public offering of its common stock that closed in April 2013. The debt financing costs are recorded in other assets on the consolidated balance sheet, net of accumulated amortization. The offering costs are recorded in equity as an offset to the proceeds received from the sale of the shares.
		(h)	Other Intangible Assets
	The Company had an acquired in-process research and development (IPR&D) intangible asset of $15.3 million as of both March 31, 2014 and December 31, 2013. Acquired IPR&D intangible assets represent the right to develop, use, sell or offer for sale intellectual property that the Company has acquired with respect to processes that have not been completed. These assets are required to be classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until their processes are completed and the Company receives regulatory approval from a major market to allow for the commencement of commercial marketing activities. At that time, the Company will determine the useful life of the asset, reclassify the asset out of in-process research and development and begin amortization. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.
	If the associated research and development effort is abandoned, the related assets likely will be written-off and the Company will record a non-cash impairment loss on its consolidated statement of operations. Acquired in-process research and development assets which are determined to have had a decrease in fair value are adjusted to fair value with an impairment charge. Such assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Intangible assets with definite useful lives will be amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company tests its IPR&D for impairment annually as of December 31 each year unless indicators, events, or circumstances would require immediate review. No impairment resulted from the Company’s most recent impairment evaluation as of December 31, 2013.
		(i)	Goodwill
	Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company had goodwill of $5.8 million as of both March 31, 2014 and December 31, 2013. The Company tests its goodwill for impairment annually as of December 31 each year unless indicators, events, or circumstances would require immediate review. No impairment resulted from the Company’s most recent impairment evaluation as of December 31, 2013.
		(j)	Property and Equipment
	Property and equipment are recorded at cost, net of depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. The following table shows the estimated useful lives of the Company’s property and equipment:
	Classification		Estimated Useful Lives
	Leasehold improvements		Lesser of useful life or lease term
	Furniture and fixtures		5 years
	Information technology related		3-5 years
	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. Repairs and maintenance costs are expensed as incurred.
		(k)	Impairment of Long-Lived Assets
	Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
		(l)	Operating Leases
	Rent expense related to leases is recorded on a straight-line basis over the term of the lease, including any rent free periods. The difference between actual rent payments and straight-line rent expense is recorded as deferred rent and included in other liabilities in the accompanying consolidated balance sheet.
		(m)	Research and Development Costs
	Research and development costs are expensed as incurred and are primarily comprised of the following types of costs incurred in performing research and development activities:
		•		employee-related expenses, including salaries, benefits, travel and share-based compensation expense;
		•		external research and development expenses incurred under arrangements with third parties, such as contract research organizations (CROs), manufacturing organizations and consultants, including our scientific advisory board; and
		•		facilities and laboratory and other supplies.
		(n)	Income Taxes
	In accordance with ASC 740, Income Taxes, each interim period is considered integral to the annual period and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. If, however, the entity is unable to reliably estimate its annual effective tax rate, then the actual effective tax rate for the year-to-date period may be the best annual effective tax rate estimate. For the three month period ended March 31, 2014, the Company utilized the actual year-to-date effective tax rate. See note 8, Income Taxes, for additional information.
		(o)	Share-Based Compensation
	The Company uses share-based compensation in the form of stock options and restricted stock. Compensation expense is recognized in the consolidated statement of operations based on the estimated fair value of the shares at grant date. Compensation cost to be recognized reflects an estimate of the number of shares expected to vest after taking into consideration an estimate of forfeiture. The fair values of stock option grants are estimated as of the date of grant using the Black-Scholes option valuation model. The fair value of option grants are based on the fair value of the Company’s common stock on the date of grant. See note 6, Stockholders’ Equity and Stock Compensation, for additional information.
		(p)	Warrant Accounting
	In connection with the loan agreement with Oxford Finance LLC, or Oxford, discussed in note 5, Long-term Debt, the Company granted warrants for the purchase of the Company’s common stock. The Company accounted for these common stock warrants in accordance with applicable accounting guidance provided in ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, as equity instruments based on the specific terms of the warrant agreements.
		(q)	Concentrations
	The Company maintains cash and cash equivalent balances with financial institutions which, at times, may exceed insurance limits established by the Federal Deposit Insurance Corporation. Management does not consider this to be a significant risk due to the long-standing reputation of these financial institutions.
	The Company has entered into agreements with a contract manufacturer to manufacture clinical and future commercial supplies of dalbavancin. The Company has also entered into an agreement with a contract manufacturer to supply the drug substance for dalbavancin in the form of injectable grade powder. The loss of either of these suppliers could have a material adverse effect upon the Company’s operations.

Financial_Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2014
Investments All Other Investments [Abstract]	'
Financial Instruments	'
	-3	Financial Instruments
	The following table presents information about the Company’s financial assets and liability that have been measured at fair value at March 31, 2014 and December 31, 2013, and indicates the fair value hierarchy of the valuation inputs used to determine such fair value (in thousands).
			March 31, 2014
			Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments		$	17,170	$	17,170	$	—	$	—
	Available for sale securities:
	Federal agency bonds			12,835		12,835		—		—
	Corporate commercial paper			3,998		3,998		—		—
	Corporate bonds			4,039		4,039		—		—
	Total available for sale securities		$	20,872	$	20,872	$	—	$	—
	Liabilities:
	Contingent liability		$	23,587	$	—	$	—	$	23,587
			December 31, 2013
			Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments		$	27,156	$	27,156	$	—	$	—
	Available for sale securities:
	Federal agency bonds			14,847		14,847		—		—
	Corporate commercial paper			3,998		3,998		—		—
	Corporate bonds			4,035		4,035		—		—
	Total available for sale securities		$	22,880	$	22,880	$	—	$	—
	Liabilities:
	Contingent liability		$	20,889	$	—	$	—	$	20,889
	Additional information for the Company’s recurring fair value measurements using significant unobservable inputs (Level 3 inputs) was follows (in thousands):
	Balance at December 31, 2013		$	20,889
	Contingent consideration expense			2,698
	Transfers in and/or out of Level 3			—
	Balance at March 31, 2014		$	23,587
	At March 31, 2014 and December 31, 2013, the balance of the contingent liability consideration, which reflects the fair value of the contingent milestone payment, was $23.6 million and $20.9 million, respectively. The Company’s contingent consideration is based on Level 3 inputs within the fair value hierarchy. Fair values determined based on Level 3 inputs use unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. The underlying probability of payment of the contingent liability was 95% and 85% as of March 31, 2014 and December 31, 2013, respectively. The increase in the probability was due to the unanimous recommendation of approval of dalbavancin for the treatment of ABSSSI by the U.S. Food and Drug Administration’s Anti-Infective Drugs Advisory Committee on March 31, 2014.
	Certain financial instruments reflected in the consolidated balance sheets (for example, cash, accounts payable and certain other liabilities) are recorded at cost, which approximates fair value due to their short-term nature.
	All available for sale securities have maturity dates less than one year. As of March 31, 2014, unrealized gains and losses on available for sale securities were immaterial.

Acquisition_Milestone_Payment

Acquisition - Milestone Payment	3 Months Ended
	Mar. 31, 2014
Business Combinations [Abstract]	'
Acquisition - Milestone Payment	'
	-4	Acquisition—Milestone Payment
	In December 2009, the Company acquired the rights to dalbavancin through its acquisition of all of the outstanding shares of capital stock of Vicuron from Pfizer pursuant to a stock purchase agreement (Pfizer Agreement). The Company paid total upfront consideration of $10.0 million for the shares of Vicuron and the dalbavancin inventory to be used in research. In addition, upon the successful clinical development, regulatory approval and first commercial sale of dalbavancin, in the United States or one of five major European markets, the Company is required to pay Pfizer an additional milestone payment of $25.0 million. However, under the Company’s credit agreement with PDL discussed in note 5, Long-term Debt, the Company is prohibited from making any payment to Pfizer as long as amounts are outstanding under the Company’s credit agreement with PDL. Under the Pfizer Agreement, the Company, at its sole discretion, may elect to defer the milestone payment for a period of up to five years if it delivers to Pfizer a promissory note for the full amount of such milestone payment. Interest on the outstanding principal amount of the promissory note will accrue at a rate of 10% per annum, compounded annually.

Longterm_Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Long-term Debt	'
	-5	Long-term Debt
	In March 2013, the Company and certain of its subsidiaries entered into a loan agreement with Oxford (the Oxford term loan), pursuant to which the Company’s wholly-owned Dutch subsidiaries borrowed an aggregate principal amount of $20.0 million.
	In connection with the Oxford term loan, the Company granted Oxford warrants for the purchase of 67,999 shares of the Company’s common stock at an exercise price of $8.68 per share. The warrants are exercisable for seven years from the date of issuance. The grant date fair value of the warrants was $6.42 per share as estimated using a Black-Scholes pricing model. In accordance with ASC 470-20-25-2, Debt Instruments with Detachable Warrants, the proceeds from the debt issuance were allocated between the warrants and the debt instrument based on the relative fair value. The portion allocated to the warrants is recorded as paid-in capital.
	On October 31, 2013, the Company and certain of its subsidiaries entered into a credit agreement with PDL (the PDL credit agreement), pursuant to which the Company’s wholly-owned Dutch subsidiaries borrowed an aggregate principal amount of $25.0 million (the First Tranche) and upon the satisfaction of certain conditions to funding set forth in the PDL credit agreement, will be required to borrow an additional aggregate principal amount of $15.0 million (the Second Tranche). The Company may also make a one-time election to borrow an additional aggregate principal amount of up to $30.0 million (the Delayed Draw) during the nine month period following the date on which the Company receives marketing approval of dalbavancin from the U.S. government (provided that such date, if it occurs at all, occurs on or prior to December 31, 2014) (the Second Tranche Milestone).
	The funding of the Second Tranche and the Delayed Draw are subject in each instance to the satisfaction of certain conditions set forth in the PDL credit agreement, including, without limitation, the continued accuracy of representations and warranties, no default or material adverse change having occurred, the execution and delivery of additional loan documents, if required, and the Second Tranche Milestone having occurred.
	Any amount borrowed under the credit agreement is guaranteed by the Company and certain of the Company’s subsidiaries. The loans and the guarantee obligations are secured by a lien on all or substantially all of the Company’s assets and all or substantially all of the assets of the Company’s subsidiaries (other than Durata Therapeutics Limited), as applicable, including the pledge of the equity interests in each of the Company’s direct and indirect subsidiaries to secure the applicable loan and guarantee obligations.
	The First Tranche bears interest at an annual rate equal to 14.00% until the Second Tranche Milestone occurs, if it occurs at all. Thereafter, each term loan bears interest at an annual rate equal to 12.75%. The credit agreement provides for interest-only payments payable quarterly in arrears through December 31, 2014, and payment of interest and principal in quarterly installments in the amounts specified in the PDL credit agreement starting on March 31, 2015 and continuing quarterly thereafter through September 30, 2018. The final maturity of the loan is October 31, 2018.
	The Company paid an origination fee to PDL when the Company entered into the credit agreement, which is included in deferred finance costs in other assets. At the Company’s option, the Company may elect to prepay all of the outstanding term loan plus any accrued interest, plus a prepayment penalty determined with respect to the principal amount of the term loan being prepaid. The credit agreement also provides for indemnification of PDL and the other lenders from time to time party to the credit agreement. The credit agreement also prohibits the Company from paying the $25.0 million milestone payment to Pfizer as long as amounts are outstanding under the credit agreement.
	The credit agreement also contains certain representations, warranties and covenants (including maintaining liquidity of at least $2 million) applicable to the Company and its subsidiaries. The credit agreement contains certain events of default. The obligations under the credit agreement and the other loan documents may, at PDL’s option, be accelerated upon the occurrence of certain events of default, and are automatically accelerated upon certain bankruptcy-related events of default.
	The net proceeds of the First Tranche were used to repay amounts outstanding under the Oxford loan agreement, including prepayment penalties and fees, and the remainder of the proceeds of the First Tranche has been used for general corporate purposes.

Stockholders_Equity_and_Stock_

Stockholders' Equity and Stock Compensation	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stockholders' Equity and Stock Compensation	'
	-6	Stockholders’ Equity and Stock Compensation
		(a)	Common Stock
	On April 17, 2013, the Company closed a public offering of an aggregate of 8,222,500 shares of common stock at a public offering price of $7.00 per share, including 1,072,500 shares pursuant to the exercise by the underwriters of an over-allotment option. Net proceeds were approximately $54.1 million, after deducting underwriting discounts and commissions but prior to the payment of offering expenses by the Company.
	In July 2012, the Company closed the initial public offering of its common stock pursuant to a registration statement on Form S-1, as amended. The Company sold an aggregate of 8,625,000 shares of common stock under the registration statement at a public offering price of $9.00 per share, including 1,125,000 shares pursuant to the exercise by the underwriters of an over-allotment option. Net proceeds were approximately $73.9 million, after deducting underwriting discounts and commissions but prior to the payment of offering expenses by the Company. Upon closing the initial public offering, all the then outstanding shares of the Company’s Series A Convertible Preferred Stock were converted into 9,649,738 shares of common stock.
	In December 2009, the Company issued 62,500 shares of restricted common stock to an officer in return for services to be rendered over the effective vesting period. This award fully vested in January 2011.
	Also included in common stock at March 31, 2014 were 8,991 common shares issued upon exercise of options during the three month period ended March 31, 2014 and 15,744 shares of vested restricted stock. There are 4,495 restricted shares unvested as of March 31, 2014.
		(b)	Series A Convertible Preferred Stock
	Prior to completing its initial public offering, the Company issued and sold an aggregate of 77,197,936 shares of its Series A Convertible Preferred Stock that resulted in the Company receiving cash proceeds of $77.2 million. The proceeds were used for research and development and general working capital. In July 2012, upon closing its initial public offering, all the then outstanding shares of the Company’s convertible preferred stock were converted into 9,649,738 shares of common stock.
	In July 2012, the Company’s one-for-8.000 reverse stock split became effective, effectively changing the conversion price of the Series A Convertible Preferred Stock.
		(c)	Stock Incentive Plans
	The two stock incentive plans (Incentive Plans) described in this section are the pre-IPO stock incentive plan, as amended (the Incentive Plan), and the 2012 stock incentive plan (2012 Plan). Prior to the Company’s initial public offering, the Company granted awards to eligible participants under the Incentive Plan. Following the initial public offering, the Company grants awards to eligible participants under the 2012 Plan.
	2012 Stock Incentive Plan (2012 Plan)
	In April 2012, the Company’s board of directors and stockholders approved the 2012 Plan. The 2012 Plan became effective immediately prior to the closing of the Company’s initial public offering. The 2012 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. As of March 31, 2014, the number of shares of the Company’s common stock reserved for issuance under the 2012 Plan was 247,817. This number may increase for the number of shares of the Company’s common stock subject to outstanding awards under the Company’s pre-IPO stock incentive plan, that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right. In addition, the 2012 Plan provides for an annual increase, to be added on the first day of fiscal year 2014 and each subsequent anniversary until the expiration of the 2012 Plan, equal to the lowest of 437,500 shares of the Company’s common stock, 2.75% of the number of shares of the Company’s common stock outstanding on the first day of the fiscal year and an amount determined by the board of directors. In March 2014, the Company filed a registration statement on Form S-8 to register the increase in the number of shares of common stock reserved for issuance under the 2012 Plan of 437,500 shares which became available for future issuance as of January 1, 2014.
	Pre-IPO Stock Incentive Plan (Incentive Plan)
	Upon the closing of its initial public offering, the Company ceased granting any awards under the Incentive Plan.
	The Incentive Plan provided for the granting of stock options and other stock awards of the Company to employees and consultants. General awards under the Incentive Plan consisted of a specified number of options awarded to an employee or consultant subject to the satisfaction of various vesting conditions determined and specified by the Company at the time of the award. In April 2012, the Company’s board of directors and stockholders approved an amendment to the Incentive Plan to increase the number of shares reserved for issuance under the Incentive Plan from 1,875,000 to 2,125,000.
	In April 2012, the Board resolved that all options granted under the Incentive Plan may be exercisable from the date of grant. If exercised prior to full vesting, restricted shares of common stock are issued and continue to vest in the same manner as the original options awarded. Upon termination of employment any unvested options or unvested restricted shares are immediately cancelled and available for future grant under the 2012 Plan, while vested options are exercisable for a defined period. The outstanding option grants at March 31, 2014 have a term of 10 years and generally vest over periods up to 4 years.
	Activity with respect to options was as follows:
			Shares			Weighted		Weighted
						average		average
						exercise		remaining
						price per		contractual
						share		life (years)
	Outstanding balance, December 31, 2013			2,651,886		$	4.26		7.67
	Granted			300,800			12.71		—
	Forfeited or expired			3,334			8.46		—
	Exercised			8,991			7.18		—
	Outstanding balance, March 31, 2014			2,940,361		$	5.11		7.68
	At March 31, 2014, the number of shares exercisable pursuant to outstanding options was 1,655,997, at a weighted average exercise price of $2.45 and a weighted average remaining contractual life of 6.74 years.
	The weighted-average grant date fair value of the stock options granted during the three month period ended March 31, 2014 was $6.88 per share. The Company estimated the fair value of options granted during the three month period ended March 31, 2014 using the Black-Scholes option pricing model using the following assumptions:
			Three month
			period ended
			March 31, 2014
	Risk-free interest rate			2.25	%
	Expected volatility			56	%
	Expected term (years)			7
	Expected dividend yield			0	%
	Share-based compensation expense for stock options granted to employees and directors is based on the estimated grant date fair value of options recognized ratably over the requisite service period, which is the vesting period of the award. The level of forfeitures expected to occur was estimated based on the Company’s historical experience of pre-vesting cancellations for terminated employees.
	During the three month period ended March 31, 2014, 8,991 options were exercised resulting in approximately $65,000 of proceeds to the Company.
	Share-based compensation expense totaled $0.8 million and $0.6 million for the three month periods ended March 31, 2014 and 2013, respectively, which is included in research and development and general and administrative expenses in the accompanying consolidated statement of operations. The aggregate intrinsic value of shares outstanding and exercisable was $24.6 million and $18.2 million as of March 31, 2014. The intrinsic value was calculated as the difference between the fair value of the underlying common stock as of the respective balance sheet date and the exercise price of the stock options. The total unrecognized share-based compensation cost at March 31, 2014 amounted to $6.1 million, net of forfeitures, which is expected to be recognized over a weighted-average remaining vesting period of approximately 2.88 years.

Net_Loss_Per_Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	-7	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss available (attributable) to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss available (attributable) to common stockholders by the weighted average number of common stock equivalents during the period. The Company’s potentially dilutive shares, which include outstanding stock options, common stock warrants and unvested restricted stock are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.
	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2014 and 2013, as they would be anti-dilutive.
			March 31,
			2014		2013
	Stock options, warrants, and unvested restricted stock			3,012,855		2,437,796

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	-8	Income Taxes
	The Company has historically computed interim period tax expense by applying its forecasted effective tax rate to year-to-date earnings. However, for the three month period ended March 31, 2014 the Company determined it was unable to reliably estimate its annual effective tax rate due to the effective tax rate being highly sensitive to minor fluctuations in forecasted income. As such, the Company has computed its tax expense for the three month period ended March 31, 2014 using the actual year-to-date effective tax rate. The effective tax rate for the three month period ended March 31, 2014 was negative 0.66%. This effective tax rate differs from the federal tax rate of 35% primarily due to the effects of foreign loss that are not benefited, state taxes, foreign rate differential, as well as items that are deductible for books and not U.S. tax. The Company recorded income tax expense of $0.1 million and $0.2 million for the three month period ended March 31, 2014 and 2013, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	-9	Commitments and Contingencies
		(a)	Employment Agreements
	The Company has employment agreements with certain employees which require the funding of a specified level of payments, if certain events (such as a change in control) or termination without cause occur.
		(b)	Consulting and Other Business Arrangements
	In the course of normal business operations, the Company has agreements with contract service providers to assist in the performance of its research and development and manufacturing activities. The Company can elect to discontinue the work under these agreements at any time. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require up-front payments and even long-term commitments of cash.
	The Company has entered into a supply agreement, as amended, with Gnosis Bioresearch srl., or Gnosis, to supply it with the drug substance for dalbavancin in the form of injectable grade powder. Gnosis has agreed to produce a specified percentage of the Company’s worldwide demand for drug substance. Under this agreement, Gnosis is required to manufacture and supply, and the Company is required to purchase specified minimum annual purchase volumes of drug substance at specified prices. The agreement expires on June 12, 2017, subject to automatic renewal for successive two-year periods. The Company currently has purchase commitments of approximately $28.7 million associated with the first three years of the initial five-year term of the agreement. The Company has agreed with Gnosis to define the purchase commitments for the subsequent two years of the initial term by a date specified in the agreement. As of March 31, 2014, the Company has incurred approximately $5.6 million under the purchase commitments in this contract of which the Company has paid $2.3 million. The remaining contracted amounts are estimated to be paid from 2014 through 2016. The Company has also identified possible secondary suppliers of drug substance and is currently engaged in a technology transfer process. The Company has entered into agreements with potential secondary suppliers of drug substance to manufacture registration and validation batches. The Company has purchase commitments of up to approximately $7.2 million under these agreements. As of March 31, 2014, we have incurred $0.8 million under these agreements.
	The Company has entered into a development and supply agreement with Hospira Worldwide, Inc., or Hospira, for its fill and finish services. Under this agreement, Hospira is required to supply and the Company is required to purchase a specified percentage of its commercial requirements of dalbavancin. The Company is also required to pay Hospira aggregate development fees of approximately $1.7 million based on the occurrence of specified milestone events. As of December 31, 2013, the Company had incurred the full commitment related to the development fee, which has been included in research and development expense in the consolidated statement of operations. The agreement expires five years after the first commercial sale of dalbavancin, subject to an automatic renewal for an indefinite period.
		(c)	Leasing Arrangements
	During 2012, the Company entered into a lease for office space in Chicago, Illinois, which the Company uses for corporate and commercial functions. The Company has agreed to pay aggregate rental fees of approximately $1.2 million over the 65 month term. The Company has provided a security deposit in the form of a letter of credit for the benefit of the landlord in the amount of $0.5 million, which amount will be reduced incrementally over the term of the lease. Also during 2012, the Company entered into a lease for office space in Branford, Connecticut, which the Company uses for research and development, clinical and regulatory functions. The Company has agreed to pay aggregate rental fees of approximately $1.8 million over the 62 month term. The Company has provided a security deposit in the form of a letter of credit for the benefit of the landlord in the amount of $0.6 million because the landlord financed leasehold improvements in excess of the construction allowance during that period. The amount will be reduced incrementally over the term of the lease.
	The letters of credit outstanding are collateralized with certificates of deposit.
	As of March 31, 2014, the remaining future commitment under these leases is $2.4 million.
		(d)	Contingencies
	From time to time, the Company may be involved in various legal actions arising out of the ordinary conduct of business. In the opinion of management, the ultimate disposition of such actions will not materially affect the Company’s consolidated financial position, results of operations or cash flows.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	-10	Subsequent Events
	The Company has evaluated subsequent events occurring after the balance sheet date through the date the financial statements were issued. Based on the evaluation, the Company has determined there were no material events or transactions that require recognition or disclosure in the consolidated financial statements.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation, Principles of Consolidation and Unaudited Interim Results	'
		(a)	Basis of Presentation, Principles of Consolidation and Unaudited Interim Results
	The unaudited accompanying consolidated financial statements of the Company are prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the SEC) and generally accepted accounting principles in the United States of America (GAAP) for condensed consolidated financial information. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments which are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. All intercompany accounts and transactions have been eliminated. These financial statements should be read in connection with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 as filed with the SEC on March 14, 2014.
	The results for the three month period ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period or for any other future year.
Use of Estimates	'
		(b)	Use of Estimates
	The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates.
Development Stage Company	'
		(c)	Development Stage Company
	The Company’s primary activities since inception have been organizing and staffing the Company, business planning, raising capital and acquiring and developing dalbavancin. Accordingly, the Company is considered to be in the “development stage” and has prepared the accompanying consolidated financial statements in accordance with the provisions of the Financial Accounting Standards Board’s (FASB) Accounting Standards Codification (ASC) No. 915, Accounting for Development Stage Entities.
Cash and Cash Equivalents and Restricted Cash	'
		(d)	Cash and Cash Equivalents and Restricted Cash
	The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains its cash resources principally in money market funds.
	Cash accounts with any type of restriction are classified as restricted cash. If restrictions are expected to be lifted in the next twelve months, the restricted cash account is classified as current. Included within restricted cash and prepaid expenses and other current assets on the Company’s consolidated balance sheet are certificates of deposit for a total of $1.1 million as of each March 31, 2014 and December 31, 2013, which are being held by a third party bank as collateral for the irrevocable letters of credit issued in connection with the Company’s two office leases (see note 9, Commitments and Contingencies).
Financial Instruments	'
		(e)	Financial Instruments
	The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is established that prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs:
	Level 1:		Observable inputs such as quoted prices in active markets for identical assets or liabilities;
	Level 2:		Inputs other than the quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly; and
	Level 3:		Unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. See note 3, Financial Instruments, for additional information.
Short-term Investments	'
		(f)	Short-term Investments
	As of March 31, 2014, cash equivalents and short-term investments consist of investments in money market accounts, federal agency bonds and corporate entity commercial paper and bonds that are classified as available for sale pursuant to ASC 320, Investments—Debt and Equity Securities. The Company classifies investments available to fund current operations as current assets on its balance sheet. Investments are classified as long-term assets on the balance sheet if (i) the Company has the intent and ability to hold the investments for a period of at least one year and (ii) the contractual maturity date of the investments is greater than one year. All of the Company’s investments are classified as current.
	The fair value of these securities is based on quoted prices for identical or similar assets. If a decline in the fair value is considered other-than-temporary the unrealized loss, if any, would be transferred from other comprehensive loss to the statement of operations. There were no charges taken for other-than-temporary declines in fair value of short-term investments during the three month period ended March 31, 2014. Realized gains and losses are determined using the specific identification method and are included in interest income in the statement of operations. Realized gains and losses recognized during the three month period ended March 31, 2014 were immaterial.
	The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers its intent to sell, or whether it is more likely than not that the Company will be required to sell, the investment before recovery of the investment’s amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, the severity and the duration of the impairment and changes in value subsequent to year end. As of December 31, 2013, there were no investments with a fair value that was lower than the amortized cost basis or any investments that had been in an unrealized loss position for a significant period. See note 3, Financial Instruments, for further information.
Deferred Financing Costs	'
		(g)	Deferred Financing Costs
	The Company capitalizes certain legal, accounting and other fees that are directly associated with in-process debt and equity financings as current assets until such financings occur. In the case of an equity financing, after occurrence, these costs are recorded in equity, net of proceeds received. In the case of a debt financing, these costs are recorded as other assets and amortized to interest expense over the term of the debt.
	As of March 31, 2014, the Company recorded debt financing costs of $0.4 million in connection with the debt financing completed in October 2013. The debt financing costs recorded in connection with the debt financing completed in March 2013 were expensed at the time the debt was repaid (see note 5, Long-term Debt, for more information). The Company also incurred offering costs of $0.4 million in connection with the public offering of its common stock that closed in April 2013. The debt financing costs are recorded in other assets on the consolidated balance sheet, net of accumulated amortization. The offering costs are recorded in equity as an offset to the proceeds received from the sale of the shares.
Other Intangible Assets	'
		(h)	Other Intangible Assets
	The Company had an acquired in-process research and development (IPR&D) intangible asset of $15.3 million as of both March 31, 2014 and December 31, 2013. Acquired IPR&D intangible assets represent the right to develop, use, sell or offer for sale intellectual property that the Company has acquired with respect to processes that have not been completed. These assets are required to be classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until their processes are completed and the Company receives regulatory approval from a major market to allow for the commencement of commercial marketing activities. At that time, the Company will determine the useful life of the asset, reclassify the asset out of in-process research and development and begin amortization. The useful life of an amortizing asset generally is determined by identifying the period in which substantially all of the cash flows are expected to be generated.
	If the associated research and development effort is abandoned, the related assets likely will be written-off and the Company will record a non-cash impairment loss on its consolidated statement of operations. Acquired in-process research and development assets which are determined to have had a decrease in fair value are adjusted to fair value with an impairment charge. Such assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment. Intangible assets with definite useful lives will be amortized to their estimated residual values over their estimated useful lives and reviewed for impairment if certain events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company tests its IPR&D for impairment annually as of December 31 each year unless indicators, events, or circumstances would require immediate review. No impairment resulted from the Company’s most recent impairment evaluation as of December 31, 2013.
Goodwill	'
		(i)	Goodwill
	Goodwill represents the excess of purchase price over fair value of net assets acquired in a business combination accounted for by the acquisition method of accounting and is not amortized, but subject to impairment testing at least annually or when a triggering event occurs that could indicate a potential impairment. The Company had goodwill of $5.8 million as of both March 31, 2014 and December 31, 2013. The Company tests its goodwill for impairment annually as of December 31 each year unless indicators, events, or circumstances would require immediate review. No impairment resulted from the Company’s most recent impairment evaluation as of December 31, 2013.
Property and Equipment	'
		(j)	Property and Equipment
	Property and equipment are recorded at cost, net of depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. The following table shows the estimated useful lives of the Company’s property and equipment:
	Classification		Estimated Useful Lives
	Leasehold improvements		Lesser of useful life or lease term
	Furniture and fixtures		5 years
	Information technology related		3-5 years
	Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized. Repairs and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets	'
		(k)	Impairment of Long-Lived Assets
	Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Operating Leases	'
		(l)	Operating Leases
	Rent expense related to leases is recorded on a straight-line basis over the term of the lease, including any rent free periods. The difference between actual rent payments and straight-line rent expense is recorded as deferred rent and included in other liabilities in the accompanying consolidated balance sheet.
Research and Development Costs	'
		(m)	Research and Development Costs
	Research and development costs are expensed as incurred and are primarily comprised of the following types of costs incurred in performing research and development activities:
		•		employee-related expenses, including salaries, benefits, travel and share-based compensation expense;
		•		external research and development expenses incurred under arrangements with third parties, such as contract research organizations (CROs), manufacturing organizations and consultants, including our scientific advisory board; and
		•		facilities and laboratory and other supplies.
Income Taxes	'
		(n)	Income Taxes
	In accordance with ASC 740, Income Taxes, each interim period is considered integral to the annual period and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. If, however, the entity is unable to reliably estimate its annual effective tax rate, then the actual effective tax rate for the year-to-date period may be the best annual effective tax rate estimate. For the three month period ended March 31, 2014, the Company utilized the actual year-to-date effective tax rate. See note 8, Income Taxes, for additional information.
Share-Based Compensation	'
		(o)	Share-Based Compensation
	The Company uses share-based compensation in the form of stock options and restricted stock. Compensation expense is recognized in the consolidated statement of operations based on the estimated fair value of the shares at grant date. Compensation cost to be recognized reflects an estimate of the number of shares expected to vest after taking into consideration an estimate of forfeiture. The fair values of stock option grants are estimated as of the date of grant using the Black-Scholes option valuation model. The fair value of option grants are based on the fair value of the Company’s common stock on the date of grant. See note 6, Stockholders’ Equity and Stock Compensation, for additional information.
Warrant Accounting	'
		(p)	Warrant Accounting
	In connection with the loan agreement with Oxford Finance LLC, or Oxford, discussed in note 5, Long-term Debt, the Company granted warrants for the purchase of the Company’s common stock. The Company accounted for these common stock warrants in accordance with applicable accounting guidance provided in ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, as equity instruments based on the specific terms of the warrant agreements.
Concentrations	'
		(q)	Concentrations
	The Company maintains cash and cash equivalent balances with financial institutions which, at times, may exceed insurance limits established by the Federal Deposit Insurance Corporation. Management does not consider this to be a significant risk due to the long-standing reputation of these financial institutions.
	The Company has entered into agreements with a contract manufacturer to manufacture clinical and future commercial supplies of dalbavancin. The Company has also entered into an agreement with a contract manufacturer to supply the drug substance for dalbavancin in the form of injectable grade powder. The loss of either of these suppliers could have a material adverse effect upon the Company’s operations.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Estimated Useful Lives of Property and Equipment	'
	The following table shows the estimated useful lives of the Company’s property and equipment:
	Classification	Estimated Useful Lives
	Leasehold improvements	Lesser of useful life or lease term
	Furniture and fixtures	5 years
	Information technology related	3-5 years

Financial_Instruments_Tables

Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Investments All Other Investments [Abstract]	'
Financial Assets and Liabilities Measured at Fair Value and Fair Value Hierarchy of Valuation Inputs Used to Determine Fair Value	'
	The following table presents information about the Company’s financial assets and liability that have been measured at fair value at March 31, 2014 and December 31, 2013, and indicates the fair value hierarchy of the valuation inputs used to determine such fair value (in thousands).
		March 31, 2014
		Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments	$	17,170	$	17,170	$	—	$	—
	Available for sale securities:
	Federal agency bonds		12,835		12,835		—		—
	Corporate commercial paper		3,998		3,998		—		—
	Corporate bonds		4,039		4,039		—		—
	Total available for sale securities	$	20,872	$	20,872	$	—	$	—
	Liabilities:
	Contingent liability	$	23,587	$	—	$	—	$	23,587
		December 31, 2013
		Fair Value		Level 1		Level 2		Level 3
	Assets:
	Money market fund investments	$	27,156	$	27,156	$	—	$	—
	Available for sale securities:
	Federal agency bonds		14,847		14,847		—		—
	Corporate commercial paper		3,998		3,998		—		—
	Corporate bonds		4,035		4,035		—		—
	Total available for sale securities	$	22,880	$	22,880	$	—	$	—
	Liabilities:
	Contingent liability	$	20,889	$	—	$	—	$	20,889
Fair Value Measurements Using Significant Unobservable Inputs	'
	Additional information for the Company’s recurring fair value measurements using significant unobservable inputs (Level 3 inputs) was follows (in thousands):
	Balance at December 31, 2013	$	20,889
	Contingent consideration expense		2,698
	Transfers in and/or out of Level 3		—
	Balance at March 31, 2014	$	23,587

Stockholders_Equity_and_Stock_1

Stockholders' Equity and Stock Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Options Activity	'
	Activity with respect to options was as follows:
		Shares			Weighted		Weighted
					average		average
					exercise		remaining
					price per		contractual
					share		life (years)
	Outstanding balance, December 31, 2013		2,651,886		$	4.26		7.67
	Granted		300,800			12.71		—
	Forfeited or expired		3,334			8.46		—
	Exercised		8,991			7.18		—
	Outstanding balance, March 31, 2014		2,940,361		$	5.11		7.68
Assumptions for Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model	'
	The Company estimated the fair value of options granted during the three month period ended March 31, 2014 using the Black-Scholes option pricing model using the following assumptions:
		Three month
		period ended
		March 31, 2014
	Risk-free interest rate		2.25	%
	Expected volatility		56	%
	Expected term (years)		7
	Expected dividend yield		0	%

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding	'
	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding as of March 31, 2014 and 2013, as they would be anti-dilutive.
		March 31,
		2014		2013
	Stock options, warrants, and unvested restricted stock		3,012,855		2,437,796

Nature_of_Business_Organizatio1

Nature of Business, Organization and Liquidity - Additional Information (Detail) (USD $)	3 Months Ended		53 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Oct. 31, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'	'	'	'	'
Revenues	'	'	$0	'	'
Net loss	-19,957,000	-15,767,000	-189,398,000	'	'
Accumulated deficit during the development stage	189,398,000	'	189,398,000	169,441,000	'
Additional borrowing capacity available	15,000,000	'	15,000,000	'	'
Optional additional borrowing capacity available	$30,000,000	'	$30,000,000	'	$30,000,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
	Lease
Summary Of Significant Accounting Policies [Line Items]	'	'
Certificates of deposit	$1,100,000	$1,100,000
Number of office leases	2	'
Charges taken for other-than-temporary declines in fair value of short-term investments	0	'
Realized gains or losses on available for sale securities	0	'
Investments with fair value	'	0
Impairment of other intangible assets	'	0
Goodwill	5,811,000	5,811,000
Impairment of goodwill	'	0
Debt Financing [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Deferred financing costs	400,000	'
Equity Financing [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Deferred financing costs	400,000	'
In-Process Research and Development [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Acquired in-process research and development intangible assets	$15,300,000	$15,300,000
Minimum [Member]	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'
Contractual maturity date of investments	'1 year	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)	3 Months Ended			12 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
	Leasehold Improvements [Member]	Furniture and Fixtures [Member]	Minimum [Member]	Maximum [Member]
			Information Technology Related [Member]	Information Technology Related [Member]
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Estimated Useful Lives, Leasehold improvements	'Lesser of useful life or lease term	'	'	'
Estimated Useful Lives	'	'5 years	'3 years	'5 years

Financial_Instruments_Financia

Financial Instruments - Financial Assets and Liabilities Measured at Fair Value and Fair Value Hierarchy of Valuation Inputs Used to Determine Fair Value (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:	'	'
Assets, Fair Value	$20,872	$22,880
Contingent Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	23,587	20,889
Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	17,170	27,156
Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	12,835	14,847
Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	3,998	3,998
Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	4,039	4,035
Level 1 [Member]	'	'
Assets:	'	'
Assets, Fair Value	20,872	22,880
Level 1 [Member] | Contingent Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 1 [Member] | Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	17,170	27,156
Level 1 [Member] | Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	12,835	14,847
Level 1 [Member] | Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	3,998	3,998
Level 1 [Member] | Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	4,039	4,035
Level 2 [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Contingent Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 2 [Member] | Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 2 [Member] | Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Contingent Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	23,587	20,889
Level 3 [Member] | Money Market Fund Investments [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Federal Agency Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Corporate Commercial Paper [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Corporate Bonds [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'

Financial_Instruments_Fair_Val

Financial Instruments - Fair Value Measurements Using Significant Unobservable Inputs (Detail) (Level 3 [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Level 3 [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Beginning Balance	$20,889
Contingent consideration expense	2,698
Transfers in and/or out of Level 3	'
Ending Balance	$23,587

Financial_Instruments_Addition

Financial Instruments - Additional Information (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Financial Instruments [Line Items]	'	'
Assumed payment probability of contingent consideration liability	95.00%	85.00%
Level 3 [Member]	'	'
Financial Instruments [Line Items]	'	'
Fair value of contingent consideration liability	23,587	20,889

Acquisition_Milestone_Payment_

Acquisition - Milestone Payment - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2013	Dec. 31, 2009	Dec. 31, 2009	Mar. 31, 2014
Business Combinations [Abstract]	'	'	'	'
Total upfront consideration	'	$10	'	'
Additional milestone payment	'	$25	$25	$25
Period of milestone payment	'	'	'5 years	'
Accrued interest rate on outstanding principal amount of promissory note	14.00%	'	10.00%	'

Longterm_Debt_Additional_Infor

Long-term Debt - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
In Millions, except Share data, unless otherwise specified	Oct. 31, 2013	Mar. 31, 2014	Dec. 31, 2009	Mar. 31, 2013
Debt Disclosure [Abstract]	'	'	'	'
Aggregate principal amount borrowed	$25	'	'	$20
Common stock warrants available for grant	'	67,999	'	'
Common stock warrants exercise price	'	8.68	'	'
Fair value of warrants	'	$6.42	'	'
Common stock warrants exercisable term	'	'7 years	'	'
Additional borrowing capacity available	15	'	'	'
Optional additional borrowing capacity available	30	30	'	'
Interest rate on first tranche until second tranche milestone	14.00%	'	10.00%	'
Interest rate on entire loan after second tranche milestone	12.75%	'	'	'
Debt instrument quarterly interest-only payments end date	31-Dec-14	'	'	'
Debt instrument quarterly principal and interest payments start date	31-Mar-15	'	'	'
Debt instrument quarterly principal and interest payments end date	30-Sep-18	'	'	'
Debt instrument maturity date	31-Oct-18	'	'	'
Additional milestone payment	'	25	25	'
Minimum required liquidity	$2	'	'	'

Stockholders_Equity_and_Stock_2

Stockholders' Equity and Stock Compensation - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

53 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

Apr. 17, 2013

Jul. 31, 2012

Dec. 31, 2009

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jul. 31, 2012

Apr. 17, 2013

Jul. 31, 2012

Mar. 31, 2014

Mar. 31, 2013

Apr. 30, 2012

Apr. 30, 2012

Mar. 31, 2014

Incentive_Plan

Restricted Stock [Member]

Restricted Stock [Member]

Class A Preferred Stock [Member]

Class A Preferred Stock [Member]

Underwriters Exercise of Over-allotment Option [Member]

Underwriters Exercise of Over-allotment Option [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

Stock Incentive Plan [Member]

2012 Plan [Member]

Vested [Member]

Unvested [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock sold under IPO and Secondary offering

8,222,500

8,625,000

'

'

'

'

'

'

'

'

1,072,500

1,125,000

'

'

'

'

'

Initial public offering and Secondary offering price per share

$7

$9

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from public offering

$54,100,000

'

'

'

'

$128,016,000

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from initial public offering

'

73,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding Preferred Stock converted into common stock

'

9,649,738

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of restricted common shares issued

'

'

62,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of restricted stock

'

'

'

'

'

'

15,744

4,495

'

'

'

'

'

'

'

'

'

Number of options exercised

'

'

'

8,991

'

'

'

'

'

'

'

'

8,991

'

'

'

'

Convertible preferred stock issued

'

'

'

'

'

'

'

'

77,197,936

'

'

'

'

'

'

'

'

Proceeds from issuance of convertible preferred stock

'

'

'

'

'

77,198,000

'

'

77,200,000

'

'

'

'

'

'

'

'

Reverse stock split

'

'

'

'

'

'

'

'

'

'one-for-8.000

'

'

'

'

'

'

'

Number of stock incentive plans

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock reserved for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,875,000

2,125,000

247,817

Number of shares of common stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

437,500

Percentage of number of shares of common stock outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.75%

Number of shares of common stock issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

437,500

Stock option outstanding granted, contractual term

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

Stock option outstanding granted, vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

Number of outstanding options exercisable

'

'

'

'

'

'

'

'

'

'

'

'

1,655,997

'

'

'

'

Weighted average exercise price of exercisable options

'

'

'

'

'

'

'

'

'

'

'

'

$2.45

'

'

'

'

Weighted average remaining contractual life (years) of exercisable options

'

'

'

'

'

'

'

'

'

'

'

'

'6 years 8 months 27 days

'

'

'

'

Weighted-average grant date fair value of the stock options granted

'

'

'

'

'

'

'

'

'

'

'

'

$6.88

'

'

'

'

Proceeds from stock options exercised

'

'

'

65,000

48,000

266,000

'

'

'

'

'

'

65,000

'

'

'

'

Share-based compensation expense for stock options

'

'

'

779,000

558,000

5,903,000

'

'

'

'

'

'

800,000

600,000

'

'

'

Aggregate intrinsic value of shares, outstanding

'

'

'

'

'

'

'

'

'

'

'

'

24,600,000

'

'

'

'

Aggregate intrinsic value of shares, exercisable

'

'

'

'

'

'

'

'

'

'

'

'

18,200,000

'

'

'

'

Unrecognized share-based compensation cost

'

'

'

'

'

'

'

'

'

'

'

'

$6,100,000

'

'

'

'

Expected period of compensation cost to be recognized

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 10 months 17 days

'

'

'

'

Stockholders_Equity_and_Stock_3

Stockholders' Equity and Stock Compensation - Stock Options Activity (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Exercised, Shares	8,991	'
Stock Incentive Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Outstanding beginning balance, Shares	2,651,886	'
Granted, Shares	300,800	'
Forfeited or expired, Shares	3,334	'
Exercised, Shares	8,991	'
Outstanding ending balance, Shares	2,940,361	2,651,886
Outstanding beginning balance, Weighted average exercise price per share	$4.26	'
Granted, Weighted average exercise price per share	$12.71	'
Forfeited or expired, Weighted average exercise price per share	$8.46	'
Exercised, Weighted average exercise price per share	$7.18	'
Outstanding ending balance, Weighted average exercise price per share	$5.11	$4.26
Outstanding balance, Weighted average remaining contractual life (years)	'7 years 8 months 5 days	'7 years 8 months 1 day

Stockholders_Equity_and_Stock_4

Stockholders' Equity and Stock Compensation - Assumptions for Estimated Fair Value of Options Granted Using Black-Scholes Option Pricing Model (Detail) (Stock Incentive Plan [Member])	3 Months Ended
	Mar. 31, 2014
Stock Incentive Plan [Member]	'
Estimated Fair Value Of Financial Instruments [Line Items]	'
Risk-free interest rate	2.25%
Expected volatility	56.00%
Expected term (years)	'7 years
Expected dividend yield	0.00%

Net_Loss_Per_Share_Dilutive_Se

Net Loss Per Share - Dilutive Securities Excluded from Computations of Diluted Weighted Average Shares Outstanding (Detail) (Stock Options, Warrants and Unvested Restricted Stock [Member])	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock Options, Warrants and Unvested Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive shares excluded from the computations of diluted weighted average shares outstanding	3,012,855	2,437,796

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		53 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'	'	'
Effective tax rate	-0.66%	'	'
Federal tax rate	35.00%	'	'
Income tax expense	$131	$248	($4,402)

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2012
			Purchase Commitments [Member]	Secondary Supplier Purchase Commitments [Member]	Chicago, Illinois [Member]	Branford, Connecticut [Member]
Commitments And Contingencies [Line Items]	'	'	'	'	'	'
Purchase commitments associated with the three years	'	'	$28,700,000	$7,200,000	'	'
Initial term of supply agreement, in year	'5 years	'	'	'	'	'
Renewal term of supply agreement, in year	'2 years	'	'	'	'	'
Expiration date of purchase agreement	12-Jun-17	'	'	'	'	'
Amount of development fees incurred during the year	'	'	5,600,000	'	'	'
Contract amount paid	'	'	2,300,000	'	'	'
Cash paid for commitments purchased	3,955,000	3,367,000	800,000	'	'	'
Aggregate development fees required to be paid	1,700,000	'	'	'	'	'
Agreement expires period	'5 years	'	'	'	'	'
Rental fees	'	'	'	'	1,200,000	1,800,000
Amount of letter of credit on lease agreements	'	'	'	'	500,000	600,000
Rental fees, month term	'	'	'	'	'65 months	'62 months
Future commitment lease	$2,400,000	'	'	'	'	'